• Je něco špatně v tomto záznamu ?

Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis

A. Berti, M. Alsawas, T. Jawaid, LJ. Prokop, JM. Lee, GH. Jeong, LF. Quintana, S. Moiseev, A. Vaglio, V. Tesar, D. Geetha, JIL. Shin, A. Kronbichler

. 2022 ; 37 (11) : 2190-2200. [pub] 2022Oct19

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu metaanalýza, systematický přehled, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22033032

BACKGROUND: Uncertainties exist about the use of mycophenolate mofetil (MMF) in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV), particularly for remission maintenance. METHODS: Systematic review and meta-analysis of phase II and III trials assessing the use of MMF in AAV, granulomatosis with polyangiitis and microscopic polyangiitis (MPA). A comprehensive search of several databases (Medline, EMBASE, Cochrane, Web of Science, Scopus) from inception to 5 May 2020 has been conducted. Trial data were extracted to estimate odds ratios (ORs) and estimates (ES) for MMF efficacy (remission-induction and maintenance). Severe adverse effects (SAEs) were collected. RESULTS: From 565 articles captured, 10 met the predefined criteria, 5 phase II and 5 III trials; 4 assessed remission-induction, 3 remission maintenance and 3 both. The pooled OR for remission-induction at 6 months was 1.06 (95% confidence interval 0.74, 1.52), with no significant difference by subgroup meta-analysis of trials stratified by different study-level features (i.e. kidney disease, MPA, myeloperoxidase-ANCA positivity, newly diagnosed disease) (P > 0.05). The overall ES for remission maintenance at the end of follow-up ranged between 51% and 91% (I2 = 74.8%). Subgroup meta-analysis identified kidney involvement as a possible source of heterogeneity, yielding a significantly higher rate of sustained remission in trials enrolling only patients with kidney involvement (92%, 76-100%) versus those enrolling patients with and without kidney involvement (56%, 45-66%). Results were similar in multiple sensitivity analyses. During follow-up, the frequency of SAEs in MMF-based treatment arms was 31.8%. CONCLUSIONS: In AAV, MMF use was significantly associated with higher sustained remission rates in trials enrolling only patients with kidney involvement. These findings might influence clinical practice.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22033032
003      
CZ-PrNML
005      
20230131150902.0
007      
ta
008      
230120s2022 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/ndt/gfab357 $2 doi
035    __
$a (PubMed)34910216
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Berti, Alvise $u Santa Chiara Regional Hospital and Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Rheumatology, Trento, Italy
245    10
$a Induction and maintenance of remission with mycophenolate mofetil in ANCA-associated vasculitis: a systematic review and meta-analysis / $c A. Berti, M. Alsawas, T. Jawaid, LJ. Prokop, JM. Lee, GH. Jeong, LF. Quintana, S. Moiseev, A. Vaglio, V. Tesar, D. Geetha, JIL. Shin, A. Kronbichler
520    9_
$a BACKGROUND: Uncertainties exist about the use of mycophenolate mofetil (MMF) in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitis (AAV), particularly for remission maintenance. METHODS: Systematic review and meta-analysis of phase II and III trials assessing the use of MMF in AAV, granulomatosis with polyangiitis and microscopic polyangiitis (MPA). A comprehensive search of several databases (Medline, EMBASE, Cochrane, Web of Science, Scopus) from inception to 5 May 2020 has been conducted. Trial data were extracted to estimate odds ratios (ORs) and estimates (ES) for MMF efficacy (remission-induction and maintenance). Severe adverse effects (SAEs) were collected. RESULTS: From 565 articles captured, 10 met the predefined criteria, 5 phase II and 5 III trials; 4 assessed remission-induction, 3 remission maintenance and 3 both. The pooled OR for remission-induction at 6 months was 1.06 (95% confidence interval 0.74, 1.52), with no significant difference by subgroup meta-analysis of trials stratified by different study-level features (i.e. kidney disease, MPA, myeloperoxidase-ANCA positivity, newly diagnosed disease) (P > 0.05). The overall ES for remission maintenance at the end of follow-up ranged between 51% and 91% (I2 = 74.8%). Subgroup meta-analysis identified kidney involvement as a possible source of heterogeneity, yielding a significantly higher rate of sustained remission in trials enrolling only patients with kidney involvement (92%, 76-100%) versus those enrolling patients with and without kidney involvement (56%, 45-66%). Results were similar in multiple sensitivity analyses. During follow-up, the frequency of SAEs in MMF-based treatment arms was 31.8%. CONCLUSIONS: In AAV, MMF use was significantly associated with higher sustained remission rates in trials enrolling only patients with kidney involvement. These findings might influence clinical practice.
650    _2
$a lidé $7 D006801
650    _2
$a kyselina mykofenolová $x terapeutické užití $7 D009173
650    _2
$a protilátky proti cytoplazmě neutrofilů $7 D019268
650    _2
$a peroxidasa $7 D009195
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    12
$a ANCA-asociované vaskulitidy $x farmakoterapie $7 D056648
650    12
$a mikroskopická polyangiitida $7 D055953
650    _2
$a indukce remise $7 D012074
655    _2
$a metaanalýza $7 D017418
655    _2
$a systematický přehled $7 D000078182
655    _2
$a časopisecké články $7 D016428
700    1_
$a Alsawas, Mouaz $u Evidence-Based Practice Center, Mayo Clinic, Rochester, MN, USA $u Department of Pathology, University of Iowa, IA City, IA, USA
700    1_
$a Jawaid, Tabinda $u Evidence-Based Practice Center, Mayo Clinic, Rochester, MN, USA
700    1_
$a Prokop, Larry J $u Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA
700    1_
$a Lee, Jiwon M $u Korea Disease Control and Prevention Agency, Division of Rare Disease Management, Cheongju-si, Republic of Korea
700    1_
$a Jeong, Gwang Hun $u College of Medicine, Gyeongsang National University, Jinju, Republic of Korea
700    1_
$a Quintana, Luis F $u Reference Center in Complex Glomerular Disease of the National Health System (CSUR), Nephrology and Renal Transplantation Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain, Institut d'Investigacions Biomediques August Pi I Sunyer (IDIBAPS), Barcelona, Spain $1 https://orcid.org/0000000175828476
700    1_
$a Moiseev, Sergey $u Tareev Clinic of Internal Diseases, Sechenov First Moscow State Medical University, Moscow, Russia
700    1_
$a Vaglio, Augusto $u Department of Biomedical Experimental and Clinical Sciences 'Mario Serio', University of Firenze, and Nephrology Unit, Meyer Children's Hospital, Firenze, Italy
700    1_
$a Tesar, Vladimir $u Department of Nephrology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czechia
700    1_
$a Geetha, Duvuru $u Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
700    1_
$a Shin, Jae I L $u Department of Pediatrics, Yonsei University College of Medicine, Seoul, Republic of Korea $1 https://orcid.org/0000000323261820
700    1_
$a Kronbichler, Andreas $u Department of Medicine, University of Cambridge, Cambridge, UK $u Vasculitis and Lupus Clinic, Addenbrooke's Hospital, Cambridge University Hospitals, Cambridge, UK
773    0_
$w MED00010288 $t Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association $x 1460-2385 $g Roč. 37, č. 11 (2022), s. 2190-2200
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34910216 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230120 $b ABA008
991    __
$a 20230131150858 $b ABA008
999    __
$a ok $b bmc $g 1891666 $s 1184367
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2022 $b 37 $c 11 $d 2190-2200 $e 2022Oct19 $i 1460-2385 $m Nephrology, dialysis, transplantation $n Nephrol Dial Transplant $x MED00010288
LZP    __
$a Pubmed-20230120

Najít záznam

Citační ukazatele

Možnosti archivace